1.
|
5 p, 324.7 KB |
The European Cancer Patient's Bill of Rights, update and implementation 2016
/
Højgaard, Liselotte (Kobenhavns Universitet) ;
Löwenberg, Bob (Erasmus University Medical Center) ;
Selby, Peter (University of Leeds) ;
Lawler, Mark (European Cancer Concord) ;
Banks, Ian (University of Leeds) ;
Law, Kate (European Cancer Concord) ;
Albreht, Tit (Institut za varovanje zdravja Republike Slovenija) ;
Armand, Jean-Pierre (Gustave Roussy) ;
Barbacid, Mariano (Centro Nacional de Investigaciones Oncológicas) ;
Barzach, Michèle (IHU Strasbourg Board of Trustees) ;
Bergh, Jonas (Karolinska Institutet (Estocolm, Suècia)) ;
Cameron, David (University of Edinburgh) ;
Conte, Pierfranco (Istituto Oncologico Veneto) ;
de Braud, Filippo (National Cancer Institute) ;
de Gramont, Aimery (Institut Hospitalier Franco-Britannique) ;
De Lorenzo, Francesco (European Cancer Patient Coalition) ;
Diehl, Volker (Universität zu Köln) ;
Diler, Sarper (Myeloma Patients Europe) ;
Erdem, Sema (Europa Donna) ;
Geissler, Jan (European Patients Academy on Therapeutic Innovation) ;
Gore-Booth, Jola (EuropaColon) ;
Henning, Geoffrey (EuropaColon) ;
Horgan, Denis (European Alliance for Personalised Medicine) ;
Jassem, Jacek (Medical University of Gdansk) ;
Johnson, Peter (Cancer Research UK) ;
Kaasa, Stein (Norges Teknisk-Naturvitenskapelige Universitet) ;
Kapitein, Peter (Inspire2Live) ;
Karjalainen, Sakari (Association of European Cancer Leagues) ;
Kelly, Joan (Irish Cancer Society) ;
Kienesberger, Anita (Austrian Childhood Cancer Organisation) ;
La Vecchia, Carlo (Universita degli Studi di Milano) ;
Lacombe, Denis (European Organisation for Research and Treatment of Cancer) ;
Lindahl, Tomas (Francis Crick Institute) ;
Luzzatto, Lucio (Universita degli Studi di Firenze) ;
Malby, Rebecca (London South Bank University) ;
Mastris, Ken (Europa Uomo) ;
Meunier, Françoise (European Organisation for Research and Treatment of Cancer) ;
Murphy, Martin (Society for Translational Oncology) ;
Naredi, Peter (European Cancer Organisation) ;
Nurse, Paul (Francis Crick Institute) ;
Oliver, Kathy (International Brain Tumour Alliance) ;
Pearce, Jonathan (Lymphoma Association) ;
Pelouchov, Jana (European Cancer Patient Coalition) ;
Piccart, Martine (Institut Jules Bordet) ;
Pinedo, Bob (VuMC Cancer Center) ;
Spurrier-Bernard, Gilly (Melanoma Patient Network Europe) ;
Sullivan, Richard (Kings Health Partners Integrated Cancer Centre) ;
Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ;
Van de Velde, Cornelis (Leids Universitair Medisch Centrum) ;
van Herk, Bert (Spaarne Gasthuis) ;
Vedsted, Peter (Aarhus Universitet) ;
Waldmann, Anita (Leukaemiehilfe RHEIN-MAIN) ;
Weller, David (University of Edinburgh) ;
Wilking, Nils (Skåne University Hospital (Suècia)) ;
Wilson, Roger (Sarcoma Patients EuroNet EV) ;
Yared, Wendy (Association of European Cancer Leagues) ;
Zielinski, Christoph C (European Society for Medical Oncology) ;
zur Hausen, Harald (University of Heidelberg) ;
Le Chevalier, Thierry (Institute Gustave Roussy) ;
Johnston, Patrick (European Cancer Concord) ;
Universitat Autònoma de Barcelona
In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative: The key aspects of working towards implementing the BoR are:.
2017 - 10.1136/esmoopen-2016-000127
ESMO open, Vol. 1 (january 2017)
|
|
2.
|
14 p, 4.6 MB |
A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
/
Lazar, Vladimir (Gustave-Roussy Cancer Center (France)) ;
Rubin, Eitan (Ben-Gurion University of the Negev (Israel)) ;
Depil, Stephane (Leon Berard Cancer Center (France)) ;
Pawitan, Yudi (Karolinska Institutet (Estocolm, Suècia)) ;
Martini, Jean-François (Pfizer Oncology Research (USA)) ;
Gomez-Navarro, Jesus (Takeda Pharmaceuticals International Co.(USA)) ;
Yver, Antoine (AstraZeneca Pharmaceuticals LP (USA)) ;
Kan, Zhengyin (Pfizer Oncology Research (USA)) ;
Dry, Jonathan R. (AstraZeneca Pharmaceuticals LP (USA)) ;
Kehren, Jeanne (Sanofi (France)) ;
Validire, Pierre (Institut Mutualiste Montsouris (France)) ;
Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ;
Vielh, Philippe (Gustave-Roussy Cancer Center (France)) ;
Ducreux, Michel (Gustave-Roussy Cancer Center (France)) ;
Galbraith, Susan (AstraZeneca Pharmaceuticals LP (USA)) ;
Lehnert, Manfred (Takeda Pharmaceuticals International Co. (USA)) ;
Onn, Amir (Chaim Sheba Medical Center (Israel)) ;
Berger, Raanan (Chaim Sheba Medical Center (Israel)) ;
Pierotti, Marco A. (Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)) ;
Porgador, Angel (Ben-Gurion University of the Negev (Israel)) ;
Pramesh, C. S. (Tata Memorial Centre (India)) ;
Ye, Ding-wei (Fudan University Shanghai Cancer Center (China)) ;
Carvalho, Andre L. (Barretos Cancer Hospital. Fundacao Pio XII (Brazil)) ;
Batist, Gerald (Jewish General Hospita. Segal Cancer Centre (Canada)) ;
Le Chevalier, Thierry (Gustave-Roussy Cancer Center (France)) ;
Morice, Philippe (Gustave-Roussy Cancer Center (France)) ;
Besse, Benjamin (Gustave-Roussy Cancer Center (France)) ;
Vassal, Gilles (Gustave-Roussy Cancer Center (France)) ;
Mortlock, Andrew (AstraZeneca Pharmaceuticals LP (USA)) ;
Hansson, Johan (Karolinska Institutet (Estocolm, Suècia)) ;
Berindan Neagoe, Ioana (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ;
Dann, Robert (General Electric Healthcare (USA)) ;
Haspel, Joel (Oracle Corporation (UK)) ;
Irimie, Alexandru (Universitatea de Medicină şi Farmacie Iuliu Haţieganu Cluj-Napoca (Romania)) ;
Laderman, Steve (Agilent Technologies (USA)) ;
Nechushtan, Hovav (Hadassah Hebrew University Medical Center (Israel)) ;
Al Omari, Amal S. (King Hussein Cancer Center (Jordan)) ;
Haywood, Trent (Blue Cross Blue Shield Association (USA)) ;
Bresson, Catherine (WIN Consortium (France)) ;
Soo, Khee Chee (National Cancer Centre (Singapore)) ;
Osman, Iman (New York University Langone Medical Center (USA)) ;
Mata, Hilario (MD Anderson Cancer Center (USA)) ;
Lee, Jack J. (MD Anderson Cancer Center (USA)) ;
Jhaveri, Komal (New York University Langone Medical Center (USA)) ;
Meurice, Guillaume (Gustave-Roussy Cancer Center (France)) ;
Palmer, Gary (Foundation Medicine Inc. (USA)) ;
Lacroix, Ludovic (Gustave-Roussy Cancer Center (France)) ;
Koscielny, Serge (Gustave-Roussy Cancer Center (France)) ;
Eterovic, Karina Agda (MD Anderson Cancer Center (USA)) ;
Blay, Jean-Yves (Leon Berard Cancer Center (France)) ;
Buller, Richard (Pfizer Oncology Research (USA)) ;
Eggermont, Alexander (Gustave-Roussy Cancer Center (France)) ;
Schilsky, Richard L. (American Society of Clinical Oncology (USA)) ;
Mendelsohn, John (MD Anderson Cancer Center (USA)) ;
Soria, Jean-Charles (Gustave-Roussy Cancer Center (France)) ;
Rothenberg, Mace (Pfizer Oncology Research (USA)) ;
Scoazec, Jean-Yves (Gustave-Roussy Cancer Center (France)) ;
Ki Hong, Waun (MD Anderson Cancer Center (USA)) ;
Kurzrock, Razelle (Moores Cancer Center (USA)) ;
Universitat Autònoma de Barcelona
Non-small cell lung cancer (NSCLC) is a leading cause of death worldwide. Targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. We present a novel strategy for identifying customized combinations of triplets of targeted agents, utilizing a simplified interventional mapping system (SIMS) that merges knowledge about existent drugs and their impact on the hallmarks of cancer. [...]
2015 - 10.18632/oncotarget.3741
Oncotarget, Vol. 6, no. 16 (June 2015) , p. 14139-14152
|
|